Deciphering MacTel Type 2 Progression: Biomarkers, Sigmoid Trajectories, and Implications for Therapeutic Intervention

Executive Overview

A retrospective longitudinal cohort study from University Hospital Bonn characterizes the natural history of ellipsoid zone (EZ) loss in Macular Telangiectasia Type 2 (MacTel). Analyzing 606 eyes across 327 patients with a median follow-up of 5.41 years, the researchers demonstrated that EZ loss follows a characteristic sigmoid progression trajectory spanning 30 to 40 years, with distinct structural patterns serving as predictive biomarkers for disease acceleration.

---

Key Study Parameters

• Cohort Size: 606 eyes from 327 patients (mean age: 59.8 ± 9.6 years).
• Primary End Point: Quantitative en face OCT measurement of manifest EZ loss area (mm²/year).
• Follow-up Duration: Median 5.41 years (interquartile range: 4.16–8.11 years; up to 14.9 years).

---

EZ Loss Classification & Progression Velocities

The study stratified EZ loss into four distinct structural patterns on OCT scans:

• Pattern 0 (No EZ Loss): Intact outer retinal structure.
• Pattern 1 (Pure Hyporeflectivity): Sharply demarcated hyporeflective space in the outer retina with preserved surrounding architecture.
  • Progression Rate: Slow progression at a median rate of 0.02 mm²/year (linear mixed model estimate: 0.033 mm²/year).
• Pattern 2 (Retinal Subsidence): Downward movement/subsidence of internal retinal layers into the EZ loss area with architectural disruption.
  • Progression Rate: Accelerated progression at a median rate of 0.08 mm²/year (linear mixed model estimate: 0.082 mm²/year).
• Pattern 3 (Mixed Feature): Combination of sharply demarcated hyporeflectivity and retinal subsidence.
  • Progression Rate: Fast progression at a median rate of 0.09 mm²/year (linear mixed model estimate: 0.095 mm²/year).

Clinical Takeaway: Structural subsidence of inner retinal layers (Pattern 2 or 3) is a robust sign of impending disease acceleration.

---

Sigmoid Growth Model & Inflection Dynamics

Bayesian logistic growth modeling highlighted non-linear progression dynamics over time:

• Early Phase (< 0.5 mm²): During the first ~10 years following EZ loss onset, progression remains slow and constrained predominantly to Pattern 1 morphologic features.
• Inflection Point (~0.5 mm²): Beyond an EZ loss threshold of 0.5 mm², disease activity accelerates rapidly.
• Peak Progression Velocity: Growth rates reach up to 0.16 mm²/year during intermediate stages.
• Asymptotic Limit: Progression tapers as the lesion approaches an anatomical ceiling (~4.93 mm²), corresponding to the classic MacTel area.

---

Practice Considerations for Retina Specialists

• Stratification for Encapsulated Cell Therapy: With FDA approval of revakinagene taroretcel-lwey (Encelto, Neurotech Pharmaceuticals, Inc.)—an intraocular implant delivering ciliary neurotrophic factor (CNTF)—identifying eyes transitioning from Pattern 1 to Pattern 2/3 provides a key structural window for optimal therapeutic initiation.
• Monitoring & Intereye Correlation: High correlation between intereye baseline lesion size (r = 0.68) and progression velocity (r = 0.58) indicates global, systemic, or genetic factors influencing bilateral disease behavior.
• Symmetry & Asymmetry Note: Right eyes showed slightly larger baseline lesion areas and faster progression rates, potentially related to asymmetric venous drainage dynamics through the right internal jugular system.

---